A promoter variant that silences the Duffy antigen on red cells, protecting against Plasmodium vivax malaria and causing a normal, lower neutrophil count that is routinely and wrongly treated as disease in people of African ancestry.
Most people have never heard of the Duffy blood group, even though it was discovered decades ago alongside the more familiar ABO and Rh systems. The Duffy antigen sits on the surface of red blood cells, and roughly two-thirds of Black Americans, and the great majority of people from West, Central and East Africa, lack it entirely on their red cells. This "Duffy-null" trait is not a disorder. It is an extremely common, evolutionarily favored variant with a fascinating history — and, unfortunately, a long track record of being misread as a medical problem when it is anything but.
Duffy-null status is caused by a single change in the "on-switch" (promoter) of the gene ACKR1 (also called DARC), located just upstream of where the gene's instructions begin. That switch normally works with a protein called GATA1 to turn the gene on specifically in developing red blood cells. The variant breaks the GATA1 docking site, so red cells never receive the instruction to make the Duffy protein — while every other cell type in the body, where a different switch is used, keeps making it normally. People with two copies of this variant are called Duffy-null, or Fy(a-b-): their red cells simply don't carry the Duffy antigen.
The reason Duffy-null is at or near 100% frequency across much of sub-Saharan Africa is malaria. The Duffy protein is the doorway that Plasmodium vivax, one of the major malaria parasites, uses to break into red blood cells. Without that doorway, the parasite cannot get in. This was demonstrated directly in a classic 1976 volunteer study: exposed to bites from P. vivax-infected mosquitoes, every Duffy-positive volunteer developed malaria, while every Duffy-null volunteer stayed completely uninfected. Over many centuries in regions where vivax malaria was a major killer, that protection gave Duffy-null carriers such a strong survival advantage that the variant swept through African populations almost to fixation. (It is worth noting that resistance is very strong but not absolute in every setting; rare vivax infections in Duffy-negative people have since been documented, particularly in parts of East Africa, suggesting the parasite can occasionally use other routes in.)
The same variant that blocks a malaria parasite also has a completely separate, unrelated effect: people who are Duffy-null tend to have a lower absolute neutrophil count (a type of white blood cell) than people who are Duffy-positive, even though nothing is wrong with their immune systems. This was traced directly to the Duffy-null genetic variant in a landmark 2009 study, which showed that this single gene region accounts for a large share of the well-known difference in average white blood cell counts between people of African and European ancestry. The leading explanation is that the Duffy protein, beyond its role on red cells, also helps regulate how chemokines (signaling molecules that recruit and distribute neutrophils) are buffered in the bloodstream; losing it appears to shift the balance of where neutrophils sit and circulate, not how well the body makes or uses them.
Here is where the story turns from interesting biology to a real, documented harm. Standard neutrophil count reference ranges were built mostly from studies of white populations and never accounted for Duffy status. As a result, a Duffy-null person's ordinary, lifelong-normal neutrophil count often falls below the "normal" cutoff on a standard lab report — and gets flagged as neutropenia, a word that usually signals a bone marrow problem, infection risk, or medication side effect.
This mislabeling, for decades called "benign ethnic neutropenia," has caused real, documented harm: unnecessary referrals to hematology for otherwise healthy people; unnecessary bone marrow biopsies performed to rule out disease that was never there; exclusion or delayed enrollment of Black patients from cancer clinical trials whose eligibility criteria use blood-count cutoffs that don't account for Duffy status; historical, sometimes automatic disqualification from the antipsychotic medication clozapine on the basis of a count that was never actually low for that person; and dose reductions or delays in chemotherapy driven by blood counts that looked alarming on paper but reflected normal physiology. Because these consequences fall disproportionately on Black patients, this is now recognized as a clear, correctable source of racial disparity in medical care, not a minor technicality.
Momentum for fixing this has grown substantially in hematology. Researchers have proposed retiring the term "benign ethnic neutropenia" in favor of the more precise, mechanism-based term "Duffy-null-associated neutrophil count" (DANC), and have begun publishing and validating Duffy-status-specific reference ranges so that a low-normal count in a Duffy-null person isn't automatically flagged as disease. In 2015, the FDA itself revised its monitoring rules for clozapine specifically to stop excluding people with benign ethnic neutropenia from treatment. The American Society of Hematology now runs an active initiative to validate these adjusted reference ranges more broadly and extend them to children. None of this changes the underlying message for patients: a lower neutrophil count in a person of African ancestry is, more often than not, a normal genetic trait, not a red flag — though genuinely concerning symptoms like fevers, weight loss, mouth ulcers, or a very low count (particularly below 500 cells per microliter) still deserve real medical evaluation regardless of Duffy status.
ACKR1 (atypical chemokine receptor 1, formerly DARC; 1q23.2) encodes a seven-transmembrane, G-protein-uncoupled promiscuous chemokine-binding receptor expressed on erythrocytes, postcapillary venular endothelium, cerebellar Purkinje cells and some epithelia. It is the Duffy blood group antigen and the obligate invasion receptor used by Plasmodium vivax (via the parasite's Duffy-binding protein/reticulocyte-binding-like proteins) and by Plasmodium knowlesi.
rs2814778 is a T>C substitution in the erythroid-specific GATA1 promoter, designated NM_002036.3(ACKR1):c.-67T>C in current ClinVar nomenclature (historically reported as -46T>C or -33T>C under older numbering conventions; Tournamille et al., 1995). The substitution disrupts the consensus GATA1 binding motif required for erythroid-lineage transcriptional activation, silencing ACKR1 expression specifically in the erythroid lineage while leaving expression in endothelium and other tissues intact. Homozygosity (CC) produces the Fy(a-b-)/Duffy-null erythrocyte phenotype; because the effect is erythroid-promoter-specific and recessive at the phenotype level, heterozygotes (TC) generally type as Duffy-positive.
1000 Genomes Project (phase 3) reference data show the C allele at or near fixation in West and East sub-Saharan African samples (Esan, Nigeria: 100%; Luhya, Kenya: 100%; Yoruba, Nigeria: 99.5%) and at approximately 80% in African Americans (ASW), the lower figure reflecting genetic admixture. Because the erythroid-null phenotype requires homozygosity, the proportion of individuals who are actually Duffy-null (Fy(a-b-)) is the square of the allele frequency, not the allele frequency itself: essentially 100% in the West/East African reference samples and approximately 63% in the African American sample — consistent with independent clinical estimates that roughly two-thirds of Black Americans are Duffy-null. The C allele is rare to essentially absent in European and East Asian reference panels.
Miller et al. (1976) demonstrated in a controlled challenge study that Duffy-null (FyFy) individuals were completely resistant to erythrocytic infection following bites from P. vivax-infected mosquitoes, while Duffy-positive individuals of the same and different ancestries were not, establishing the Duffy antigen as necessary for vivax invasion. Subsequent field reports have documented occasional P. vivax infections in Duffy-negative individuals in parts of Africa, indicating resistance, while very strong, is not absolute in all epidemiological settings; the mechanism of these breakthrough infections (alternative invasion pathways versus low-level Duffy expression) remains under study.
Reich, Nalls et al. (2009), using admixture mapping in African American cohorts (Jackson Heart Study, Health ABC, ARIC), localized the majority of the well-described lower mean white blood cell and absolute neutrophil counts in African-ancestry populations to a ~1 Mb region on chromosome 1 centered on rs2814778, identifying the Duffy-null genotype as the causal variant. The proposed mechanism relates to altered chemokine buffering/marginated neutrophil pool dynamics rather than impaired granulopoiesis or immune competence; Duffy-null status has not been shown to increase infection risk. The count reduction shows a gene-dose relationship, with heterozygotes having intermediate counts.
Merz and Achebe (2021) proposed retiring the term "benign ethnic neutropenia" in favor of "Duffy-null-associated neutrophil count" (DANC) to reflect the genetic, non-pathologic basis of the trait. Merz et al. (2023, JAMA) derived and validated a DANC-specific absolute neutrophil count reference interval in a cohort of self-identified Black adults, distinct from and lower than standard population reference ranges, intended to reduce inappropriate workup. Hibbs et al. (2024, JAMA Network Open) documented that oncology clinical trial eligibility criteria and treatment-modification decisions based on standard ANC cutoffs disproportionately affect individuals with DANC. In 2015 the FDA revised clozapine monitoring requirements with a separate algorithm for patients with benign ethnic neutropenia, rather than excluding them from treatment outright. The change lowered the baseline ANC needed to start treatment (1000/μL for these patients, versus 1500/μL otherwise) and allows treatment to continue at counts of 500-999/μL that would require interruption in the general population, provided the patient is at or above their own baseline. The severe-neutropenia floor at which clozapine must be stopped remains 500/μL for everyone. The American Society of Hematology has an active initiative (DANC project) to further validate adult and pediatric Duffy-status-adjusted reference ranges.
An isolated, stable, mild-to-moderate reduction in absolute neutrophil count in an asymptomatic person of African, Middle Eastern, or West Indian ancestry is, in the absence of other findings, most often DANC rather than a hematologic disorder. Features that still warrant conventional hematologic evaluation regardless of ancestry or presumed Duffy status include constitutional symptoms (fever, weight loss, night sweats), recurrent or severe infections, mucosal ulceration, other cytopenias, or an ANC persistently below 1000/μL and especially below 500/μL.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Duffy-Null Phenotype and Benign Ethnic Neutropenia comes down to these specific, well-studied positions — not a diagnosis.
It means your red blood cells don't display the Duffy blood group antigen, because you inherited two copies of a promoter variant that silences the gene specifically in red cells (it's still made normally elsewhere in the body). It's an extremely common, normal trait in people of African ancestry — not a disease.
The Plasmodium vivax malaria parasite needs to grab onto the Duffy antigen to break into red blood cells. Without that antigen, the parasite has essentially no way in. This gave Duffy-null carriers such a strong survival advantage in malaria-endemic regions that the variant became nearly universal across much of sub-Saharan Africa.
Usually not. Duffy-null status is associated with a lower baseline neutrophil count that reflects normal physiology, not impaired immune function or increased infection risk. Standard reference ranges were not built with this trait in mind, so a normal Duffy-null count is often mislabeled as abnormal.
It is the older name for this normal, Duffy-related lower neutrophil count. It is being replaced with the more precise term "Duffy-null-associated neutrophil count" (DANC) because it describes the actual genetic mechanism and avoids implying that ethnicity itself, rather than a specific and identifiable gene variant, is the cause.
Hematology specialists increasingly recommend against automatic referral, bone marrow biopsy, or treatment changes for an isolated, stable, mild-to-moderate low count with no other concerning findings, and Duffy-adjusted reference ranges are being validated across multiple institutions for broader clinical use. Fevers, weight loss, mouth ulcers, or a count persistently below 1000/μL (especially below 500/μL) still warrant standard medical evaluation.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.